We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+31.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$422M
AUM Growth
+$153M
(+57%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
26.56%
Top 10 Holdings %
Top 10 Hldgs %
59.67%
Holding
84
New
36
Increased
11
Reduced
13
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$9.63M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$5.7M |
| 3 |
VIVE
VIVEVE MED INC
VIVE
|
+$5.55M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$5.36M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$4.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$21.3M |
| 2 |
Akebia Therapeutics
AKBA
|
+$7.28M |
| 3 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
+$5.35M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$4.98M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$4.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.69% |
| 2 | Technology | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Zimmer Biomet
ZBH
$18.8B
| – | – |
-15,450
| Closed | -$1.55M |
|
|
NBSE
77
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| – | – |
-25
| Closed | -$15K |
|
|
SCTL
78
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| – | – |
-334,500
| Closed | -$2.42M |
|
|
AERI
79
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-50,000
| Closed | -$1.89M |
|
|
GWPH
80
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-40,000
| Closed | -$4.47M |
|
|
IMMU
81
CALL
DELISTED
Immunomedics Inc
IMMU
| – | – |
-100,000
| Closed | -$367K |
|
|
DERM
82
DELISTED
Dermira, Inc.
DERM
| – | – |
-88,500
| Closed | -$2.68M |
|
|
WBMD
83
DELISTED
WebMD Health Corp.
WBMD
| – | – |
-80,000
| Closed | -$4.09M |
|
|
SPNC
84
DELISTED
Spectranetics Corp
SPNC
| – | – |
-27,500
| Closed | -$674K |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q1 2017 Portfolio in Review
As of Q1 2017, Acuta Capital Partners held 84 positions worth $422M, up 57% from $269M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Acuta Capital Partners deployed $112M of net new capital in Q1 2017, opening 36 new positions and adding to 11 existing holdings. Its largest new stake was TESARO, Inc.: 35,000 shares worth $5.38M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 77% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $21.3M trimmed.
- Acuta Capital Partners's largest Q1 2017 buy was TESARO, Inc.: 35,000 shares worth $5.38M.
- Acuta Capital Partners added most to Acadia Pharmaceuticals in Q1 2017, an estimated $9.63M increase.
- Acuta Capital Partners's biggest Q1 2017 reduction was Immunomedics Inc, cutting an estimated $21.3M.
- Acuta Capital Partners fully exited Akebia Therapeutics in Q1 2017, selling an estimated $7.28M.
- Acuta Capital Partners's ten largest holdings make up 60% of its $422M portfolio in Q1 2017.
- Acuta Capital Partners opened 36 new positions and closed 17 in Q1 2017.
- Acuta Capital Partners's portfolio value rose 57% quarter-over-quarter to $422M.
Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.